WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 3rd and 4th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
A10XXOther drugs used in diabetes 01.09.20232024
C02KNOther antihypertensives01.09.20232024
C05XOTHER VASOPROTECTIVESFinal2024
C05XXOther vasoprotectivesFinal2024
L01FYCombinations of monoclonal antibodies and antibody drug conjugates01.09.20232024
L04AESphingosine 1-phosphate (S1P) receptor modulatorsFinal2024
L04AFJanus-associated kinase (JAK) inhibitorsFinal2024
L04AGMonoclonal antibodiesFinal2024
L04AHMammalian target of rapamycin (mTOR) kinase inhibitorsFinal2024
L04AJComplement inhibitorsFinal2024
L04AKDihydroorotate dehydrogenase (DHODH) inhibitorsFinal2024
N05CJ Orexin receptor antagonists Final2024

Last updated: 2023-05-11